Lucence Health

What Lucence Health does

Lucence Health is a precision oncology diagnostics company founded in 2016 as a spin-off from Singapore's Agency for Science, Technology and Research (A*STAR), with dual CLIA-certified and CAP-accredited laboratories in Singapore (global headquarters) and Palo Alto, California. The company develops and markets a portfolio of next-generation sequencing-based liquid biopsy and tissue genomic profiling tests spanning the full patient journey: hereditary cancer risk (Lumi Series), multi-cancer early detection (LucenceINSIGHT for up to 50 cancers with 99% specificity), cardiovascular and hematologic risk (CardioHemeRISK), treatment selection (LiquidHALLMARK combining ctDNA and ctRNA, HemeMARK, UNITED 600 comprehensive tissue profiling), and minimal residual disease monitoring (LucenceMONITOR).

The company's core technology is its proprietary AmpliMARK liquid biopsy platform combined with mirror barcoding chemistry, enabling ultra-deep sequencing at 10,000X depth. The primary technical differentiator is combined ctDNA and ctRNA analysis from a single blood draw, which Lucence reports detects 36.7% more actionable fusions than ctDNA-only panels. Clinical validation is anchored by the LIQUIK multicenter prospective head-to-head study, published in JCO Precision Oncology in June 2025, demonstrating 15.6% greater NCCN-recommended biomarker detection versus an FDA-approved ctDNA-only comparator.

Lucence operates a B2B2C prescription-only model in which physicians order tests through its portal; samples are shipped to its labs and results are returned to the ordering clinician. US Medicare coverage for LiquidHALLMARK (achieved 2023) and MolDX approval (January 2025) provide US reimbursement infrastructure. Distribution combines direct enterprise sales with strategic channel partnerships — Mayo Clinic Laboratories in the US, Agilus Diagnostics in India, and Partners Pathology in Malaysia — plus research collaborations with DxD Hub (A*STAR) and NCCS. The company is privately held, having raised approximately $29.2 million across a 2017 seed round and a 2019 Series A led by IHH Healthcare, with no Series B or later round publicly disclosed.

Name

Lucence Health

Legal name

Lucence Diagnostics Pte. Ltd.

Website

https://lucence.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

51–100 employees

Short description

Lucence Health is a Singapore- and US-based precision oncology company operating CLIA/CAP labs and offering NGS-based liquid biopsy and tissue profiling tests for cancer detection, treatment selection, hereditary risk, and MRD monitoring, distributed via channel partners including Mayo Clinic Labs.

Ownership category

akta.pro rank

Product category

Cancer Diagnostics and Liquid Biopsy Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing (HLAAANAG)

akta.pro secondary industries

Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC), Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays (HLAAALAN), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)

Keywords

• Liquid biopsy testing
• Cancer genomic profiling
• Multi-cancer early detection
• Hereditary cancer testing
• Treatment response monitoring

Headquarters

HQ city

Palo Alto

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. Diagnostic Laboratory Testing Services: Lucence operates CLIA-certified and CAP-accredited laboratories in Singapore and Palo Alto, CA. Physicians order Lucence's tests (prescription-only) and samples are sent to Lucence's labs for processing. Results are returned to ordering physicians who interpret and communicate findings to patients. Revenue is generated on a per-test basis. Tests are available internationally including the USA (LiquidHALLMARK) and outside the USA (LucenceINSIGHT, LiquidMARK, and others). US Medicare coverage and MolDX approval support reimbursement in the US market.

Go-to-market motion3 records

Distribution channels5 records

Marketing channels8 records

Core offering

Lucence Health provides clinical laboratory diagnostic testing services through CLIA-certified and CAP-accredited labs in Singapore and Palo Alto, California. Its core offering is liquid biopsy testing powered by its proprietary AmpliMARK platform and combined ctDNA + ctRNA next-generation sequencing, used by physicians for cancer screening, hereditary risk assessment, treatment selection, and treatment response monitoring, complemented by tissue-based comprehensive genomic profiling tests.

Product overview

Lucence Health offers a comprehensive portfolio of precision oncology and cardiovascular screening solutions powered by proprietary AmpliMARK™ liquid biopsy technology. The product lineup spans the entire patient journey: hereditary cancer risk assessment (Lumi Series: LumiRISK™, LumiFOCUS™, LumiTHERA™), screening and health risk assessment (LucenceINSIGHT® Core/12/50 for multi-cancer early detection, CardioHemeRISK™ for cardiovascular/leukemia risk, LucenceLONGEVITY™ combining both), treatment selection (LiquidHALLMARK® and LiquidMARK™ liquid biopsy tests, HemeMARK™ for hematologic cancers, UNITED™ 600 and UNITED™ CNS tissue tests, Rapid TissueMARK™, LiquidSCREEN™ Lung, NPC GOLD™), and treatment response monitoring (LucenceMONITOR™ for MRD detection). The core differentiator is the combined ctDNA and ctRNA analysis platform that enables superior detection of actionable biomarkers compared to DNA-only liquid biopsy approaches.

Differentiator

Problem solved

Functional benefit

Brands

• LiquidHALLMARK: Ultrasensitive blood test detecting tumor-derived ctDNA and ctRNA for cancer-related mutations with a single blood draw
• LucenceINSIGHT
• CardioHemeRISK
• LucenceMONITOR
• Lumi Series
• UNITED 600
• UNITED CNS
• Rapid TissueMARK
• LucenceLONGEVITY
• LiquidMARK
• HemeMARK
• LiquidSCREEN Lung
• NPC GOLD

Products and services

• LiquidHALLMARK Ultrasensitive liquid biopsy blood test analyzing 80 ctDNA genes and 37 ctRNA fusions from a single blood draw to identify actionable mutations, fusions, and biomarkers for personalized cancer therapy selection.
• LiquidMARK Focused liquid biopsy sub-panel for therapy selection in specific cancer types (lung, breast, ovarian, colon, prostate, pancreas, bile duct), using the same process as LiquidHALLMARK to detect tumor-derived ctDNA.
• HemeMARK Comprehensive NGS liquid biopsy blood test detecting biomarkers in hematological cancers to support therapy selection.
• UNITED 600 Tissue-based comprehensive genomic profiling test analyzing 572 genes and 71 RNA fusions from FFPE samples, combining DNA and RNA signals for personalized therapy selection.
• UNITED CNS Next-generation sequencing tissue test panel for classifying central nervous system (CNS) cancers in line with the WHO CNS5 standard-of-care, supporting accurate diagnosis and treatment planning.
• Rapid TissueMARK Tissue test detecting over 50 NCCN-recommended actionable biomarkers with rapid turnaround time (5 working days), covering lung, breast, ovarian, colon, prostate, pancreas, and bile duct cancers.
• LiquidSCREEN Lung Liquid biopsy EGFR mutation blood test for therapy selection in non-small cell lung cancer (NSCLC).
• LiquidHALLMARK CSF Liquid biopsy test using cerebrospinal fluid (CSF) for diagnosis and treatment selection in NSCLC patients with leptomeningeal metastasis.
• LucenceINSIGHT Multi-cancer early detection (MCED) NGS blood test screening for up to 50 cancers with 99% specificity and 80.9% sensitivity, using ctDNA, ctRNA, viral DNA, and machine learning for 88% tumor localization accuracy.
• CardioHemeRISK Liquid biopsy-based NGS blood test that detects aging and lifestyle-related clonal hematopoiesis (CH) mutations using mirror barcoding technology at 10,000X ultra-deep sequencing to assess risk of heart attack, stroke, and leukemia.
• LucenceLONGEVITY Combination screening package pairing LucenceINSIGHT 50 multi-cancer early detection with CardioHemeRISK cardiovascular and leukemia risk assessment for comprehensive multi-disease screening beyond cancer.
• LucenceMONITOR Minimal residual disease (MRD) liquid biopsy test screening for recurrence across 15 solid tumor types by detecting ctDNA and ctRNA to track tumor-specific mutations over time.
• NPC GOLD Nasopharyngeal cancer (NPC) early screening test using a single blood tube to detect NPC, particularly relevant for endemic Asian populations.
• LumiRISK Hereditary cancer risk assessment test examining 45 genes related to 11 cancers to assess an individual's risk of developing hereditary cancer at 99% sensitivity.
• LumiFOCUS Hereditary cancer risk test examining genes associated with specific cancers via cancer-specific panels, designed for individuals with a family history of particular cancer types.
• LumiTHERA Hereditary cancer test analyzing 17 guideline-recommended genes including Homologous Recombination Repair (HRR) pathway genes to match patients with US FDA-approved targeted therapies for breast, ovarian, prostate, pancreatic, and colorectal cancers.

Quantifiable outcome

• LiquidHALLMARK ctDNA + ctRNA detected 15.6% more tissue-confirmed NCCN guideline-recommended biomarkers (52/68 vs 45/68) than FDA-approved ctDNA-only test (LIQUIK study)
• +8 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature8 records

Partnerships

Eleven partnerships are on record, tiered core and minor.

• Diagnostics Development Hub (DxD Hub) — Agency for Science, Technology and Research (A*STAR)coreStrategic or Co-development Partner · 13 March 2026S$6 million research collaboration with DxD Hub and NCCS to develop UNITED 2.0 — a next-generation clinical-grade cancer profiling test using dual Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS). The collaboration builds on the original UNITED 1.0 tissue test (UNITED 600) and aims to move from gene snapshots to comprehensive cancer maps with AI-supported analysis. Over a 3-year roadmap, the collaboration will also develop MRD testing tools. DxD Hub brings end-to-end test design expertise from sample handling to analytical validation and clinical reporting.
• National Cancer Centre Singapore (NCCS)coreStrategic or Co-development Partner · 13 March 2026Research collaborator in the S$6M UNITED 2.0 collaboration alongside DxD Hub. NCCS contributes clinical expertise and patient access for developing and validating the next-generation cancer profiling test. Assistant Professor Jason Chan, Director of the Cancer Discovery Hub at NCCS, leads the collaboration. NCCS has been a research collaborator since 2021 (original UNITED 1.0).
• Brain Tumour Society Singapore (BTSS)minorStrategic or Co-development Partner · 13 March 2026Landmark MOU signed between Lucence, DxD Hub, and BTSS to establish a framework for patient perspectives to inform the R&D process for future diagnostic tools. This partnership ensures that patient needs and experiences are central to the development of cancer diagnostics, particularly for rare cancers.
• Partners PathologycoreChannel Partner/ Reseller/ Distributor · 5 March 2026Commercial partnership announced March 2026 to expand access to cancer diagnostics and personalized medicine in Malaysia. Partners Pathology offers Lucence's full suite of liquid and tissue biopsy tests including LiquidHALLMARK (80 ctDNA genes and 37 ctRNA fusions) alongside its own histopathology services. Physical presence established in Penang, Malaysia, as a regional medical hub for both local and international patients.
• Agilus DiagnosticscoreChannel Partner/ Reseller/ Distributor · 24 February 2025Strategic collaboration announced February 2025 to advance cancer testing services in India. Agilus Diagnostics provides the distribution infrastructure and customer relationships in India to expand commercial operations. This partnership was noted as part of Lucence's 2025 expansion into Indian and ASEAN markets.
• Mayo Clinic LaboratoriescoreChannel Partner/ Reseller/ Distributor · 10 January 2025Strategic collaboration announced January 2025 to enhance cancer testing services and increase LiquidHALLMARK access in the US market. Mayo Clinic Laboratories serves as a channel partner distributing Lucence's liquid biopsy tests to its extensive network of healthcare providers across the United States. Mayo Clinic is listed as a strategic collaborator on the oncologists community page.
• Innovent BiologicsminorStrategic or Co-development PartnerMentioned in news coverage of the cholangiocarcinoma market as a notable partnership between Lucence and Innovent Biologics in the context of targeted therapies and diagnostics research collaborations for cholangiocarcinoma (bile duct cancer).
• MD Anderson Cancer CenterminorStrategic or Co-development PartnerListed as a research collaborator on the oncologists community page. MD Anderson contributes to clinical validation and research studies supporting Lucence's liquid biopsy tests.
• Dana-Farber Cancer InstituteminorStrategic or Co-development PartnerListed as a research collaborator on the oncologists community page. Dana-Farber supports clinical validation of Lucence's diagnostic tests.
• Kaiser PermanenteminorStrategic or Co-development PartnerListed as a research collaborator on the oncologists community page.
• VA Palo Alto Health Care System (VAPAHCS)minorStrategic or Co-development PartnerListed as a research collaborator on the oncologists community page.

Scale indicators10 records

Recent moves10 records

Expansion highlights6 records

Direct peers

• Guardant Health: Guardant Health is the leading US liquid biopsy company (NASDAQ: GH), offering Guardant360 CDx for comprehensive genomic profiling and Guardant Reveal for MRD. It is the most direct competitor to LiquidHALLMARK and LiquidMARK, competing in the same oncology therapy-selection category with ctDNA-only panels.
• Foundation Medicine: Foundation Medicine (a Roche subsidiary) offers FoundationOne CDx and FoundationOne Liquid CDx — directly competing with Lucence's UNITED 600 tissue CGP and LiquidHALLMARK liquid biopsy tests for therapy selection in advanced cancer patients.
• Natera: Natera (NASDAQ: NTRA) operates Signatera, a leading tumor-informed MRD test directly competing with LucenceMONITOR. Natera also offers liquid biopsy panels for therapy selection, putting it in direct overlap with LiquidHALLMARK's clinical use cases.
• Tempus: Tempus offers AI-enabled precision medicine including the xT (tissue) and xF (liquid) comprehensive genomic profiling tests, directly competing with UNITED 600 and LiquidHALLMARK. Tempus also layers in multi-omic data and AI analytics analogous to Lucence's UNITED 2.0 roadmap.
• Caris Life Sciences: Caris Life Sciences offers MI Profile (tissue CGP) and MI Cancer Seek (blood-based multi-cancer screening), directly competing with Lucence's UNITED 600 and LucenceINSIGHT MCED. Caris has invested heavily in AI-driven molecular profiling similar to Lucence's roadmap.
• Personalis: Personalis (NASDAQ: PSNL) offers NeXT Personal, a tumor-informed MRD test, and CGP services for pharma/biotech. Personalis overlaps with LucenceMONITOR (MRD) and Lucence's pharma/biotech research collaborations via UNITED 2.0.
• GRAIL: GRAIL's Galleri test is a leading multi-cancer early detection (MCED) blood test, the most direct competitor to LucenceINSIGHT in the MCED category. GRAIL's ctDNA-only methylation-based approach differs from Lucence's ctDNA+ctRNA strategy.

Broad incumbents

• Exact Sciences: Exact Sciences (NASDAQ: EXAS) is a major cancer diagnostics incumbent with Cologuard (CRC screening), Oncotype DX, and the Oncodetect MRD test. It is a broad incumbent across the cancer screening and monitoring categories where Lucence competes, with materially greater commercial scale.
• NeoGenomics: NeoGenomics (NASDAQ: NEO) is a US oncology-focused clinical laboratory offering comprehensive tumor profiling (RaDaR MRD, NGS panels). It is a broad incumbent serving hospital systems and oncologists — a customer segment that overlaps directly with Lucence's LiquidHALLMARK and LucenceMONITOR markets.

Regional players

• Burning Rock Biotech: Burning Rock Biotech (NASDAQ: BNR, China-headquartered) offers liquid biopsy and tissue NGS panels for therapy selection — closely comparable to Lucence's LiquidHALLMARK. Burning Rock primarily serves Greater China, making it a regional competitor in Asian precision oncology rather than a direct US rival.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/LucenceHealth
• LinkedInlinkedin.com/company/lucence
• Xx.com/lucencedx

Compliance9 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lucence Health